TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch...
TriSalus Reports $11.6 million i n Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enables...
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for...
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Conference Call and Webcast Scheduled for Thursday November 13, 2025 at 4:30 PM
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for...
Company delivers $11.2M in revenues resulting in 52% growth year-over-year and 22% growth quarter-over-quarter Broadened PEDD portfolio...
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for...
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced...